Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Populatio
- Conditions
- Diseases of the digestive system
- Registration Number
- KCT0001262
- Lead Sponsor
- ational Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 5224
Men and women aged 40-65 who are invited to participate in the National Cancer - Screening Program and receive upper endoscopy
- Willingness to sign an informed consent form
- Good health, as determined by medical history and physical examination at enrollment
- Personal history of gastric cancer
- Family history of gastric cancer in a first degree relative
- Diagnosis and active treatment for other organ cancer except carcinoma in situ within 5 years
- Current treatment for serious medical condition which could hinder participation (such as liver cirrhosis, renal failure, pulmonary dysfunction including COPD or asthma, or uncontrolled infection)
- Inadequate cardiovascular function including (a) New York Heart Association class III or IV heart disease, (b) unstable angina or myocardial infarction history, (c) history of significant ventricular arrhythmia requiring medication with antiarrhythmics, and (d) history of cerebrovascular accident
- Requirement for therapeutic anticoagulant therapy, aspirin
- Gastric resections due to benign disease
- H. pylori eradication therapy history
- Mental incompetence to understand and sign informed consent
- Alcoholism, drug abuse
- Serious chronic diseases according to the evaluation of the study physician
- Presence of a contraindication to the use of eradication treatment regimens
- Inability to provide an informed consent
- Pregnant or lactating women
- Treatment required due to peptic ulcer, gastric cancer or esophageal cancer identified during the endoscopic examination
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The incidence of gastric cancer between the intervention and placebo groups
- Secondary Outcome Measures
Name Time Method Incidence of gastric dysplasia;Occurrence of adverse events caused by antibiotic treatment;Incidence and mortality from other medical conditions such as obesity, diabetes, circulatory diseases, oesophageal diseases as well as other cancers and cognitive impairment;Mortality from gastric cancer;All-cause mortality;Modification of atrophy score